Investment
Features
FeesSafety
Academy
More
Pluang+

Meituan's losses shrink as China curbs price wars, boosting outlook for profitability.

Analyst Insights
27 Mar 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Meituan reported a smaller company-wide deficit in Q4 2025 and expects reduced food delivery losses in Q1 2026. This improvement is supported by Chinese regulators discouraging price wars, which should enhance Meituan's future profitability. The positive regulatory environment and better financial results have led to a more optimistic investment view on Meituan's prospects.

More News

Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...

Market News
Bullish
2 hours ago
UnitedHealth beats Q2 earnings estimates, raises 2026 profit outlook with AI-driven cost control.

UnitedHealth beats Q2 earnings estimates, raises 2026 profit outlook with AI-driven cost control.

UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...

Company Fundamentals
Bullish
4 hours ago
Meta Platforms upgraded to buy on cloud business entry and strong cash flow outlook

Meta Platforms upgraded to buy on cloud business entry and strong cash flow outlook

Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...

Analyst Insights
Bullish
4 hours ago
Alnylam Pharmaceuticals rated BUY despite recent stock drop, backed by strong drug sales and solid finances.

Alnylam Pharmaceuticals rated BUY despite recent stock drop, backed by strong drug sales and solid finances.

Willow Tree Research initiates coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, viewing the recent stock price decline as an overreaction. The company’s drug AMVUTTRA holds a near-term commercial monopoly in TTR silencing, with st...

Analyst Insights
Bullish
4 hours ago
SpaceX stock dips below IPO price amid investor concerns over losses and valuation.

SpaceX stock dips below IPO price amid investor concerns over losses and valuation.

SpaceX shares fell below their IPO price of $135 for the first time, dropping to $132.28 before closing slightly above at $135.27. The stock is down about 16% from its June 12 closing price and 36% from its peak on June 16. The decline reflects inves...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App